NC-XILIS-INC
13.7.2022 14:02:12 CEST | Business Wire | Press release
Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere™ (MOS™) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million. New investor FPV Ventures led the extension, with participation from fellow new investor Alexandria Venture Investments and existing investors EQT Life Sciences, Mubadala Capital Management, Pear Ventures, GV (formerly Google Ventures), the Duke Angel Network, Catalio Capital Management, Two Sigma Ventures, Felicis Ventures, Alix Ventures and other strategic partners.
“Despite unprecedented market conditions in the biotech sector, we raised this extension at a step-up valuation and from several of the most reputable global investors. Our investors are strongly encouraged by the progress we have made in building diagnostic programs that predict patient response and achieving significant traction in partnered drug discovery and development,” said Xiling Shen, PhD, Founder and Chief Executive Officer of Xilis. “Our MOS technology is the first end-to-end, high-throughput patient-derived model drug discovery platform to identify drug candidates with a high probability of clinical success.”
The company will use the Series A funding to advance its proprietary MOS platform. This innovative MOS technology is the first truly scalable patient-derived model that recapitulates the tumor microenvironment and immune interactions necessary for next-generation immuno-oncology and cell therapy drug discovery. In addition, the MOS platform can be applied in a clinical setting to aid clinicians to make precision oncology treatment decisions, identifying treatments that lead to the best response for each patient.
“Xilis has pushed forward and achieved meaningful scientific breakthroughs that will change the way cancer drugs are being discovered and how patients are being selected to achieve the most optimal response – realizing the goal of personalized precision oncology,” said Wesley Chan, Co-Founder & Managing Partner of FPV Ventures. “With support from a world-class investor consortium, Xilis is set to continue its efforts in clinical diagnostics and accelerate the company’s growth by expanding its MOS technology into biopharma R&D and drug development.”
Recently, the company announced its participation in the Netherlands-based Oncode-PACT Consortium to accelerate the development of cancer drugs and was selected as the cover article/story in the June issue of the journal Cell Stem Cell highlighting its MOS technology and application in precision oncology.
"Xilis' innovative MOS technology can enable unlocking the full potential of patient-derived microtumors by accelerating their use both in the clinic and for drug discovery and development," said John de Koning, Partner at EQT Life Sciences. "Patients will benefit greatly from Xilis’ precision oncology treatment decisions by avoiding time spent on treatment cycles that are ineffective, and instead, receive therapies with the greatest potential of success quickly and efficiently."
About Xilis
Based in Durham, North Carolina, Xilis, Inc. is a biotechnology company developing a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients and enables drug discovery and development with pharmaceutical companies. Xilis’ proprietary MicroOrganoSphere™ (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution. Using MOS and AI-driven algorithms, Xilis is developing a Xilis Response Score™ for the clinic, enabling oncologists to make informed and timely treatment decisions. Additionally, the MOS technology is speeding up the discovery and clinical development of new drug candidates.
To learn more about Xilis, visit our website at Xilis.com or follow us on LinkedIn .
About FPV
FPV is a new $450m fund focused on backing and serving mission-driven founders throughout their entire journey. Founded by Wesley Chan (Founder of Google Analytics and Google Voice) and Pegah Ebrahimi (former COO of Morgan Stanley Tech Banking and COO of Cisco Collaboration), the firm has backed well-known, high-impact startups including Canva, Flexport, Guild Education, Xilis, and Manifold Bio.
About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.
The team combines deep sector knowledge, analytical skills, and investment experience to provide the added value that inventors seek. EQT Life Sciences’ broad life sciences and healthcare network is highly complementary to EQT’s global healthcare sector franchise and makes EQT an even better and more innovative healthcare investor. More info: www.eqtgroup.com/lifesciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005121/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom